Articles On Immutep (ASX:IMM)

Phase III trials are a major catalyst for healthcare companies, mark final proving ground before potential regulatory approval and commercialisation Success can make or break a company with several ASX healthcare names now in the high-stak...

A gaggle of drug developers is due to disclose company-making clinical study results this year While late-stage clinical trial victory does not confer commercial success, the results tend to be ‘do or die’ In the main, share valuations don...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Australian biotechs are successfully turning promising science into a scalable, repe...

The Bulls N’ Bears ASX Runner of the Week is… Bison Resources, which exploded on debut, as punters piled into its prime Nevada gold-silver projects amid ongoing fuel security chaos.

ASX crawls just 0.09% higher Financials gives up gains, unwinding market momentum Energy, utilities drag as US-Iran ceasefire continues Market struggles to hold momentum It was relatively quiet on the Middle Eastern front, with no dramati...

Highlights Market edges higher on easing oil prices Tech and gold stocks lead sector gains Energy and banks weigh on sentiment ASX 200 edged higher at midday, driven by gains in technology and gold stocks, while energy and financi...

Immutep Ltd (ASX: IMM) shares are having a rare breakout session on Wednesday. After spending most of the year under relentless selling pressure, the biotech stock has suddenly sprung back to life. At the time of writing, Immutep shar...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks...

Following the clinical trial setbacks from drug developers Opthea, Immutep, Percheron and Argenica Therapeutics, the local sector could really do with a win. Actinogen Medical (ASX:ACW) could be the one to pull the sector out of its funk –...

The Ides of March weighed down the sector, but green shoots of recovery may make April fools of the naysayers Telix Pharmaceuticals shares led the top end recovery with a 40% gain It’s April – and drug developers with names starting with ‘...

The CAR Group Ltd (ASX: CAR) share price is once again in the red on Friday. At the time of writing, shares are down 1.92% to $22.51, after falling as low as $22.19 earlier in the session. That marks a multi-year low, with the stock now...

Syrah Resources Ltd (ASX: SYR) shares are crashing deep into the red on Friday. In morning trade, the ASX mining stock is down 24% to a multi-year low of 11 cents. Why is this ASX mining stock crashing? Investors have been selling the graph...

Pancreatic cancer is normally a death sentence, but five patients in Amplia’s studies have emerged tumour free It’s a case of ‘good golly Molly’ as medical pot platform joins the psychedelics push Nexsen wins positive FDA feedback on its p...

The Bulls N’ Bears ASX Runner of the Week is… Immutep. In a slightly perverse twist, the oncology mid-cap bounced hard from last week’s 90 per cent drop, gaining 53 per cent after a brutal sell-off.

Good afternoon, and welcome to the HotCopper HotList column. Every week, ASX companies of every shape and size go through the ups and downs that is the Australian trading rollercoaster. Fortunes made, and equity lost each time the bourse op...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Oil first rallied, then retreated. Equities played the opposite card, recovering tow...

In the face of a new war crisis weighing heavily on both equities and economics alike, value hunters (both long- and short-term minded alike) are chasing down new targets for 2026. Listen to the HotCopper podcast for in-depth discussion...

Racura is well out in front on the Australian bourse topic-wise today – and has had the single biggest jump price-wise – even under what has been a brutal Thursday selling day, though it’s followed closely by another healthcare company (a w...

S&P/ASX 300 Index (ASX: XKO) healthcare stock Immutep Ltd (ASX: IMM) has been on a decidedly wild ride these past four trading days. After entering a trading halt on Monday, 9 March, Immutep shares resumed trading last Friday. And by th...

S&P/ASX 300 Index (ASX: XKO) healthcare stock Immutep Ltd (ASX: IMM) has been on a decidedly wild ride these past four trading days. After entering a trading halt on Monday, 9 March, Immutep shares resumed trading last Friday. And by th...

ASX today − Yesterday morning, I suggested Australian traders were waiting for a sign before deciding which way to go. Well, just a day later, oil’s boiling up to $110/barrel and the ASX is heading for a -1.71% collapse. Listen to the Ho...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Equities traded modestly higher overnight as cautiously optimistic investors await f...

Bell Potter has been running the rule over a number of small-cap ASX healthcare stocks this week. Let's see what the broker is saying about these speculative stocks. Immutep Ltd (ASX: IMM) Immutep is a clinical-stage biopharmaceutical comp...

ASX rises 0.36% after falling into negative territory just before the RBA decision RBA votes to rase cash rate to 4.1% in 5v4 split decision Real estate and gold stocks lead gains RBA hikes rates in split decision The Reserve Bank did exa...

S&P/ASX 200 Index (ASX: XJO) share CAR Group Ltd (ASX: CAR) is slipping today. Shares in the auto listings company closed yesterday trading for $24.21. In morning trade on Tuesday, shares are swapping hands for $24.04 apiece, down 0.4%...

Northern Star Resources Ltd (ASX: NST) shares have endured an awful past week of trading.  Last Friday, the ASX 200 gold stock fell more than 18%.  This was followed up by a 5.3% drop on Monday. Holders of Northern Star shares wou...

ASX casts defensive sectors in leading roles Oil keeps the spotlight while gold loses some shine CBA and ANZ deliver supporting performances on rate-hike expectations   The plot thickens for global markets While the Oscars played out in H...

Looking for ASX shares to buy after recent market weakness? Well, if you are, let's see what analysts are saying about the popular shares in this article, courtesy of The Bull. Are they buys, holds, or sells? Let's find out: Brainchip Hold...

Highlights Defensive sectors attract attention as commodity pressure reshapes market sentiment Energy and consumer staples display resilience in early trading activity Several small-cap companies record notable movement acro...

Highlights Energy shocks and global tensions are reshaping sentiment across Australian equities Gold and materials counters face renewed pressure amid commodity volatility Select companies gain attention as the market search...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks...

The All Ordinaries Index (ASX: XAO) is down 0.3% today, but that's not holding back this ASX All Ords stock. The outperforming stock in question is minerals and technology company Syrah Resources Ltd (ASX: SYR). Syrah Resources shares close...

Northern Star Resources Ltd (ASX: NST) shares have been struggling in recent months. Due to production issues, the ASX 200 gold giant is down 32% from its 52-week high to $21.75. While this is disappointing for shareholders, Bell Potter thi...

Northern Star Resources Ltd (ASX: NST) shares are in focus this week after the company experienced a historic crash on Friday.  The share price tumbled more than 18% in a single day.  It has now fallen more than 30% since the start of...

On Friday, the S&P/ASX 200 Index (ASX: XJO) finished the week with a small decline. The benchmark index fell 0.15% to 8,617.1 points. Will the market be able to bounce back from this on Monday? Here are five things to watch: ASX 200 e...

Highlights Market activity across the ASX revealed strong divergence among sectors. Defence technology, healthcare, and infrastructure companies led the advancing side. Mining, biotech, and investment firms featured among th...

Highlights Rising geopolitical tensions weigh on Australian equities Mining stocks face pressure while energy and defence firms gain attention Banking sector steadies market sentiment amid rate expectations Heightened...

Highlights Oil surge unsettles Australian sharemarket sentiment Mining giants face pressure from rising energy costs Banking stocks display steadier momentum Global energy developments have triggered fresh volatility a...

ASX slips 0.14% on Friday, but ends up 0.17% over the past five days Oil prices remain high, with Brent crude hovering around US$100/barrel Energy stocks rise alongside mining and banking majors   ASX stumbles to week’s end The S&P/AS...

Highlights Clinical study halt shakes confidence in biotech pipeline. Lung cancer program setback triggers sharp market reaction. Focus shifts toward remaining research programs. A halted late-stage lung cancer trial h...

ASX health sector falls about 2.5% for the past five days while broader market is just scraping by as the Middle East conflict takes a toll Immutep plunges 90% on Friday after abandoning its Phase III trial of lung cancer treatment  Pro Me...

Good Afternoon, I’m Jon Davidson, it’s a Friday and you know what that means – it’s time for HotCopper Highlights, the segment where we wrap up the stocks and company announcements you were watching and viewing the most this week on Austral...

Immutep Ltd (ASX:IMM) has seen its share price slaughtered on Friday after it’s effectively ditched its lead candidate for the treatment of lung cancer, a move that spells doom for any biotech – the speculative trader’s speculative investme...

It looks like it will be a day to forget for owners of Immutep Ltd (ASX: IMM) shares on Friday. In morning trade, the ASX biotech stock is down a massive 93% to 2.8 cents. Why is this ASX biotech stock having a day to forget? Investors have...

The Immutep Ltd (ASX: IMM) share price is currently halted on Monday. This comes after the biotech company requested a trading halt from the ASX late last week. Before being placed on ice, shares in the cancer immunotherapy develope...

Oil prices have surged as the war between the United States, Israel, and Iran intensifies across the Middle East. Brent crude and West Texas Intermediate (WTI) crude have both climbed above the US$100 per barrel mark for the first time...

Now could be the time to pounce on the ASX biotech stock in this article according to analysts at Bell Potter. That's because it believes the speculative stock could generate very big returns over the next 12 months if everything goes to pl...

ASX healthcare sector falls 13.31% in February as benchmark ASX 200 up 4% Blood products and vaccines giant CSL weighed heavily on sector down 19.1% in February Rhythm Biosciences up 48% in February to be sector’s biggest gainer for the mo...

Local life sciences players eyeing developing geographies for potentially higher returns Bioscience Managers talks Türkiye on $145 million fund Adalta’s ‘east meets west’ drug procurement strategy gains traction   As the world’s biggest h...